Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Cash Flow (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Net Cash Flow data on record, last reported at -$5.3 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 77.05% year-over-year to -$5.3 million; the TTM value through Dec 2025 reached -$4.6 million, up 69.89%, while the annual FY2025 figure was -$4.6 million, 69.89% up from the prior year.
  • Net Cash Flow reached -$5.3 million in Q4 2025 per ACRS's latest filing, down from -$146000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $78.2 million in Q2 2021 and bottomed at -$59.8 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$1.4 million, with a median of -$2.3 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 465.24% in 2021, then crashed 2854.3% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$26.3 million in 2021, then surged by 37.62% to -$16.4 million in 2022, then soared by 105.12% to $838000.0 in 2023, then plummeted by 2854.3% to -$23.1 million in 2024, then skyrocketed by 77.05% to -$5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$5.3 million in Q4 2025, -$146000.0 in Q3 2025, and -$5.0 million in Q2 2025.